# ResMed Inc. (RMD) FY2027 Q1 P&L / Income Statement

- Company: ResMed Inc. (RMD)
- Period: 2026-07-01 to 2026-09-30
- Filing: Q1 FY2027 10-Q, filed 2026-10-30, accession number 0000943819-26-000089
- Page: https://plicit.ai/financials/rmd/fy2027-q1-income-statement
- Chart image: https://plicit.ai/charts/rmd-fy2027-q1-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-07-01 through 2026-09-30. View: Product and service. Revenue and costs use their disclosed categories.

- **Net revenue**: 1,414,814,000 US dollars
- **Cost of sales**: 544,247,000 US dollars
- **Gross profit**: 870,567,000 US dollars
- **Total operating expenses**: 417,583,000 US dollars
- **Income from operations**: 452,984,000 US dollars
- **Total other income (loss), net**: 86,171,000 US dollars
- **Income before income taxes**: 539,155,000 US dollars
- **Income taxes**: 120,742,000 US dollars
- **Net income**: 418,413,000 US dollars
- **Sleep and Breathing Health revenue**: 1,259,802,000 US dollars
- **Residential Care Software revenue**: 155,012,000 US dollars
- **Sleep and Breathing Health cost of revenue**: 493,879,000 US dollars
- **Residential Care Software cost of revenue**: 50,368,000 US dollars
- **Total operating expenses**: 417,583,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Business Segment

- Page: https://plicit.ai/financials/rmd/fy2027-q1-income-statement/revenue-by-business-segment
- Chart image: https://plicit.ai/charts/rmd-fy2027-q1-revenue-by-business-segment-sankey.png

Income statement for 2026-07-01 through 2026-09-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenue**: 1,414,814,000 US dollars
- **Cost of sales**: 544,247,000 US dollars
- **Gross profit**: 870,567,000 US dollars
- **Total operating expenses**: 417,583,000 US dollars
- **Income from operations**: 452,984,000 US dollars
- **Total other income (loss), net**: 86,171,000 US dollars
- **Income before income taxes**: 539,155,000 US dollars
- **Income taxes**: 120,742,000 US dollars
- **Net income**: 418,413,000 US dollars
- **Total Sleep and Breathing Health**: 1,259,802,000 US dollars
- **Residential Care Software**: 155,012,000 US dollars
- **Total operating expenses**: 417,583,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Business Segment by Geography

- Page: https://plicit.ai/financials/rmd/fy2027-q1-income-statement/revenue-by-business-segment-by-geography
- Chart image: https://plicit.ai/charts/rmd-fy2027-q1-revenue-by-business-segment-by-geography-sankey.png

Income statement for 2026-07-01 through 2026-09-30. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenue**: 1,414,814,000 US dollars
- **Cost of sales**: 544,247,000 US dollars
- **Gross profit**: 870,567,000 US dollars
- **Total operating expenses**: 417,583,000 US dollars
- **Income from operations**: 452,984,000 US dollars
- **Total other income (loss), net**: 86,171,000 US dollars
- **Income before income taxes**: 539,155,000 US dollars
- **Income taxes**: 120,742,000 US dollars
- **Net income**: 418,413,000 US dollars
- **Residential Care Software**: 155,012,000 US dollars
- **Sleep and Breathing Health - Rest of World**: 426,383,000 US dollars
- **Sleep and Breathing Health - Americas**: 833,419,000 US dollars
- **Total operating expenses**: 417,583,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Business Segment by Subsegment

- Page: https://plicit.ai/financials/rmd/fy2027-q1-income-statement/revenue-by-business-segment-by-subsegment
- Chart image: https://plicit.ai/charts/rmd-fy2027-q1-revenue-by-business-segment-by-subsegment-sankey.png

Income statement for 2026-07-01 through 2026-09-30. View: Segments by Subsegments. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenue**: 1,414,814,000 US dollars
- **Cost of sales**: 544,247,000 US dollars
- **Gross profit**: 870,567,000 US dollars
- **Total operating expenses**: 417,583,000 US dollars
- **Income from operations**: 452,984,000 US dollars
- **Total other income (loss), net**: 86,171,000 US dollars
- **Income before income taxes**: 539,155,000 US dollars
- **Income taxes**: 120,742,000 US dollars
- **Net income**: 418,413,000 US dollars
- **Residential Care Software**: 155,012,000 US dollars
- **Sleep and Breathing Health - Devices**: 720,292,000 US dollars
- **Sleep and Breathing Health - Masks and other**: 539,510,000 US dollars
- **Total operating expenses**: 417,583,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Key Takeaways

- Net income rose $69.88 M to $418.41 M, but a $54.92 M after-tax gain supplied 79% of it.
- Operating income rose only 1.4%, to $452.98 M, while net income rose 20%.
- Gross margin edged up to 61.5%, helped partly by lower amortization after the MatrixCare sale.
- Selling, general and administrative costs rose to 22.2% of sales, from 21.1% a year earlier.
- Other income, net, supplied $86.17 M this quarter, against $0.26 M a year earlier.

## The Unvarnished Truth

### A one-time gain carried most of ResMed's 20% profit jump.

Net income rose 20% to $418.41 M, and that headline reads like a turnaround. The engine underneath is smaller. Operating income, the profit from the main business before interest and gains, rose only 1.4%, to $452.98 M. The gap was filled by a $61.78 M gain on the sale of MatrixCare, which the filing calls non-recurring. After tax, that gain is $54.92 M, which accounts for 79% of the rise in net income.

Tax did not help. The effective rate rose to 22.4% from 22.0%, and the filing points to global minimum taxes and discrete items. Spending moved up too: research and development rose 15% to $102.86 M, and selling, general and administrative costs rose 12% to $314.72 M. The filing's gross margin story is tied to the sale too: the MD&A credits lower amortization of acquired intangibles after MatrixCare, which means a piece of the margin gain comes from the sale rather than the core.

Sales grew 6% this quarter, and the profit that outran them was booked from a sale, not from selling more. The company's own non-GAAP figure strips the gain and adds back restructuring and amortization, and it shows net income of $418.01 M, about 11% above a year earlier. The next quarter without a gain is the real test. Without the MatrixCare gain, what will profit look like if research and selling costs keep climbing faster than sales?

## Intelligent Insights for Investors

### How much of ResMed's profit comes from its main business?

About 84% of it: its main business earned $452.98 M this quarter, and interest, investments and other items, led by gain on divestment of subsidiaries, added the rest.

### Did a lower tax rate drive ResMed's profit growth?

No: its tax rate rose to 22.4% this quarter from 22.0% a year earlier. Profit after tax therefore grew more slowly than profit before income taxes.

### Is ResMed investing more or less in research and equipment than before?

It is spending more on both, as a share of sales: research and development came to 7.3% of sales this quarter (6.7% a year earlier), and property and equipment spending came to 3.4% (3.2% a year earlier).

## Intelligent Insights for Lenders

### Does ResMed earn enough to cover its interest payments?

Yes: its operating profit covered its interest 94.1 times this quarter, against 62.7 times a year earlier.

## Intelligent Insights for Employees

### Are ResMed's overhead and selling costs falling as a share of sales?

No: selling and overhead costs took 22.2% of sales this quarter, up from 21.1% a year earlier.

## Intelligent Insights for Customers

### What does ResMed sell, and how much of each?

Above all, Sleep and Breathing Health, at 89% of sales this quarter. Next is Residential Care Software, at 11%.
